Q3 2023 Results - Reimagining Medicine
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Financial performance
Immunology
ianalumab - BAFF-R inhibitor
Conclusions
NCT05648968 VAYHIA (CVAY736012301)
Warm autoimmune hemolytic anemia
Phase 3
Indication
Phase
Patients
90
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Binary variable indicating whether a patient achieves a durable response
Durable response: hemoglobin level ≥10 g/dL and ≥2 g/dL increase from
baseline, for a period of at least eight consecutive weeks between W9 and
W25, in the absence of rescue medication or prohibited treatment
Arm 1: experimental lanalumab low dose (intravenously)
Arm 2: experimental lanalumab high dose (intravenously)
Arm 3: placebo Comparatorn (intravenously)
Previously treated patients with warm Autoimmune Hemolytic Anemia
Readout
Milestone(s)
Publication
2026
TBD
68 Investor Relations | Q3 2023 Results
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation